Celiac Disease in Patients With Cystic Fibrosis on Ivacaftor: A Case Series
Overview
Authors
Affiliations
Cystic fibrosis transmembrane conductance regulator (CFTR) protein modulators have revolutionized care for individuals with cystic fibrosis (CF) with positive effects on the gastrointestinal (GI) tract. There is emerging evidence linking CFTR dysfunction to celiac disease (CD). We present 3 cases of patients with CF, genotype F508del/G551D, treated with CFTR modulator, ivacaftor, and diagnosed with CD. These patients tested for CD because they had persistent GI symptoms that had partially improved with ivacaftor. This case series highlights the importance of a better understanding of how CFTR modulators impact the GI tract, their possible link to CD, and the importance of considering CD when evaluating GI symptoms in individuals with CF.
Blaseg N, Robson J, Patel R, Asfour F, Pohl J Cureus. 2024; 16(4):e59018.
PMID: 38800303 PMC: 11127755. DOI: 10.7759/cureus.59018.
Diagnosis and Management of Gastrointestinal Manifestations in Children with Cystic Fibrosis.
Anton-Paduraru D, Murgu A, Bozomitu L, Mindru D, Iliescu Halitchi C, Trofin F Diagnostics (Basel). 2024; 14(2).
PMID: 38275475 PMC: 10814426. DOI: 10.3390/diagnostics14020228.
Understanding Cystic Fibrosis Comorbidities and Their Impact on Nutritional Management.
Patel D, Shan A, Mathews S, Sathe M Nutrients. 2022; 14(5).
PMID: 35268004 PMC: 8912424. DOI: 10.3390/nu14051028.
Treatment of cystic fibrosis related bone disease.
Ullal J, Kutney K, Williams K, Weber D J Clin Transl Endocrinol. 2022; 27:100291.
PMID: 35059303 PMC: 8760456. DOI: 10.1016/j.jcte.2021.100291.